In our experimental conditions, PARP-1 inhibition by 3-AB treatment was associated with a very important decrease in OX-42 staining at 4 h (Fig. 4B1–2) and 24 h (Fig. 4D1–2) of ischemia as compared to vehicle treated animals. The gene discussed is PARP1; the disease is ischemia.